Opportunity Costs of Receiving Palliative Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma

PURPOSE: The median overall survival (OS) for metastatic pancreatic ductal adenocarcinoma (mPDAC) is < 1 year. Factors that contribute to quality of life during treatment are critical to quantify. One factor—time spent obtaining clinical services—is understudied. We quantified total outpatient ti...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:JCO Oncol Pract
Auteurs principaux: Bange, Erin M., Doucette, Abigail, Gabriel, Peter E., Porterfield, Florence, Harrigan, James J., Wang, Robin, Wojcieszynski, Andrzej P., Boursi, Ben, Mooney, Bethany I., Reiss, Kim A., Mamtani, Ronac
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2020
Sujets:
ORIGINAL CONTRIBUTIONS
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7427417/
https://ncbi.nlm.nih.gov/pubmed/32130074
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JOP.19.00328
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires